Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin Combinations for Disseminated MAC in AIDS
NCT00001058Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of clarithromycin in Mycobacterium avium complex disease (MAC) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Complete microbiologic response at 12 weeks. Status: completed.
02
Drugs
clarithromycin
03
Conditions
Mycobacterium avium complex disease (MAC)
Beyond the preview
Go deeper on NCT00001058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001058.